Evolent Health, Inc
EVH Healthcare Health Information Services
Evolent Health, Inc’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 26.6% from fiscal 2024. In the quarter to June 2026, revenue grew 46.9%, EPS grew 43.2%, free cash flow grew 58.7% and total debt rose 49.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow EVH
Evolent Health, Inc (EVH) EV/Sales
As of 16 October 2026, Evolent Health, Inc (EVH) trades at a EV/Sales of 0.6×. Over the past ten years it has ranged from 0.0× (September 2015) to 9.7× (November 2015); the current reading is higher than 10% of that period. That is below the Health Information Services industry median of 2.6× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.7× | 5.20% |
| FY2024 | 0.6× | (69.63%) |
| FY2023 | 2.1× | 2.90% |
| FY2022 | 2.0× | (18.46%) |
| FY2021 | 2.5× | 77.85% |
| FY2020 | 1.4× | 4.75% |
| FY2019 | 1.3× | (39.46%) |
| FY2018 | 2.2× | 48.68% |
| FY2017 | 1.5× | (34.85%) |
| FY2016 | 2.3× | 20.90% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.7× | 21.86% |
| Mar 2026 | 0.6× | (15.51%) |
| Dec 2025 | 0.7× | (27.22%) |
| Sep 2025 | 0.9× | 13.02% |
| 41 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MDRX Veradigm Inc. compare | 0.6× |
| EVH Evolent Health, Inc | 0.6× |
| PHR Phreesia, Inc. compare | 1.5× |
| CSLT Castlight Health, inc. compare | 1.9× |
| WEAV Weave Communications, Inc. compare | 2.0× |
| NRC National Research Corporation compare | 3.8× |
| CARL Carlsmed, Inc. compare | 4.6× |
| CTEV Claritev Corporation compare | 5.0× |
| SOPH SOPHiA GENETICS SA compare | 5.1× |
| Health Information Services industry median | 2.6× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)